Topical cenegermin 0.002% for pediatric neurotrophic keratopathy

Elhusseiny, Abdelrahman M.; Traish, Aisha S.; Saeed, Hajirah N.; Mantagos, Iason S.

doi:10.1177/11206721221094783

Cited by 5 publications

(3 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Novel medical and surgical interventions have been recently proposed for the management of NK such as topical cenegermin and corneal neurotization. 10,11 However, none of the above novel therapies were used in our case series. Table 1 summarizes the baseline and clinical characteristics and outcomes for patients in this study.…”

Section: Discussionmentioning

confidence: 99%

Neurotrophic Keratopathy After Slow Coagulation Transscleral Cyclophotocoagulation

Sayed

Khodeiry

Elhusseiny

et al. 2023

Cornea

Self Cite

View full text Add to dashboard Cite

Purpose: Decreased corneal sensation and subsequent neurotrophic keratopathy (NK) is an uncommon complication after transscleral cyclophotocoagulation (TSCPC). Post-TSCPC NK has been rarely reported in the literature, predominantly after traditional, “pop technique” continuous-wave TSCPC or micropulse CPC. The authors report the first case series of NK after slow-coagulation TSCPC (SC-TSCPC). Methods: This was a respective chart review of patients who developed NK after SC-TSCPC. The collected data included demographic data, type of glaucoma, risk factors for corneal anesthesia in addition to the number of laser spots, and the extent of the treated area. Results: Four eyes experienced NK after SC-TSCPC. The median time for the development of NK was 4 weeks. At the final visit, 2 patients had a resolution of NK, 1 had a persistent corneal ulcer, and 1 had worsening NK and corneal perforation. Conclusions: NK is a rare but a vision-threatening complication that can develop after SC-TSCPC in patients with risk factors for decreased corneal sensation. Early diagnosis and proper management are crucial to reducing the risk of vision loss and improving the prognosis of these cases.

show abstract

Section: Discussionmentioning

confidence: 99%

Neurotrophic Keratopathy After Slow Coagulation Transscleral Cyclophotocoagulation

Sayed

Khodeiry

Elhusseiny

et al. 2023

Cornea

Self Cite

View full text Add to dashboard Cite

show abstract

“…Clinical trials have also explored their application in diseases such as glaucoma and retinitis pigmentosa with cystoid macular oedema. Recently, the safety and effectiveness of rh-NGF have also been demonstrated in children and adolescents [ 43 , 44 ]. The wide range of potential that these drops offer is a great hope for the treatment of various eye diseases.…”

Section: Discussionmentioning

confidence: 99%

Level of Secretion and the Role of the Nerve Growth Factor in Patients with Keratoconus before and after Collagen Fibre Cross-Linking Surgery

Krok,

Wróblewska-Czajka,

Łach-Wojnarowicz

et al. 2023

IJMS

View full text Add to dashboard Cite

Background: The aim of this study was to analyse the concentration of the nerve growth factor (NGF-β) in patients with keratoconus (KC) who are undergoing collagen fibre cross-linking (CXL) surgery in order to better understand the pathogenesis of this disease and observe the molecular changes occurring after the procedure. Among many cytokines, β-NGF seems to play an important role in the healing processes of corneal damage. Therefore, its role in the regenerative process after CXL treatment may affect the course of treatment and its final results. Tear samples from 52 patients were collected in this prospective study. Additionally, the patients also had a number of tests performed, including corneal topography using optical coherence tomography. Flat (K 1), steep (K 2), cylindrical (CYL), and central corneal thickness (CCT) keratometry were assessed. The tear samples were collected, and other tests were performed before the CXL procedure and afterwards, during the 12-month follow-up period. The NGF concentration was measured using the Bio-Plex Magnetic Luminex Assay. Lower levels of NGF-β were detected in the KC patients than in the control group (p < 0.001). The day after the procedure, the NGF-β level was significantly lower (on average by 2.3 pg/mL) (p = 0.037) than before the procedure, after which, the level of the reagent increases, but only in the group with the advanced cone, one month after CXL it was significantly higher (p = 0.047). Regarding the correlation of NGF with topographic measurements, the following were found: NGF-β correlates significantly (p < 0.05) and positively (r > 0) with K1 before the CXL procedure; NGF-β correlates significantly (p < 0.05) and positively (r > 0) with K1 one month after CXL; NGF-β correlates significantly (p < 0.05) and positively (r > 0) with CYL nine months after CXL; and, after twelve months, NGF-β correlates significantly (p < 0.05) and positively (r > 0) with K2 and K1. Corneal sensitivity did not statistically and significantly correlate with the level of NGF-β secretion. Our study suggests that NGF may be crucial in the development and progression of KC as well as in the repair mechanisms after CXL surgery. Further research is needed on the role of NGF and other inflammatory biomarkers for rapid diagnosis and selection of targeted therapy in patients with keratoconus.

show abstract

“…evaluated the efficacy of cenegermin drops in a retrospective study on four pediatric patients after failure of the classic medical therapy. In all cases, at the end of treatment, a marked improvement of the epitheliopathy was demonstrated with a general improvement of corneal signs and symptoms ( 43 ).…”

Section: Clinical Studies On the Cenegermin Treatment Of Nkmentioning

confidence: 97%

The use of rh-NGF in the management of neurotrophic keratopathy

Roszkowska,

Spinella,

Calderone

et al. 2024

Front. Ophthalmol.

View full text Add to dashboard Cite

Neurotrophic keratitis or keratopathy (NK) is a degenerative corneal disease induced by impairment of the trigeminal nerve function. This condition may lead to persistent epithelial defects, corneal ulceration, and perforation. The diagnosis of NK requires a careful investigation of any ocular and systemic condition associated with the disease and ocular surface and corneal sensitivity examinations. In the past, several medical and surgical procedures were used to treat this condition with different clinical effectiveness. Cenegermin is a recombinant human nerve growth factor (rh-NGF) that supports corneal reinnervation. Different clinical trials have demonstrated the safety and efficacy of topical cenegermin in patients with moderate to severe neurotrophic keratitis. In this review, we report the literature on clinical results regarding the treatment of NK with cenegermin since its approval by the European Medicines Agency (EMA) and the Food and Drug Administration (FDA) in 2017 and 2018, respectively.

show abstract

Topical cenegermin 0.002% for pediatric neurotrophic keratopathy

Cited by 5 publications

References 16 publications

Neurotrophic Keratopathy After Slow Coagulation Transscleral Cyclophotocoagulation

Neurotrophic Keratopathy After Slow Coagulation Transscleral Cyclophotocoagulation

Level of Secretion and the Role of the Nerve Growth Factor in Patients with Keratoconus before and after Collagen Fibre Cross-Linking Surgery

The use of rh-NGF in the management of neurotrophic keratopathy

Contact Info

Product

Resources

About